Wockhardt is currently trading at Rs. 1285.00, up by 12.70 points or 1.00% from its previous closing of Rs. 1272.30 on the BSE.
The scrip opened at Rs. 1275.00 and has touched a high and low of Rs. 1290.50 and Rs. 1272.00 respectively. So far 62415 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1290.50 on 17-Aug-2012 and a 52 week low of Rs. 251.25 on 06-Jan-2012.
Last one week high and low of the scrip stood at Rs. 1290.50 and Rs. 1167.50 respectively. The current market cap of the company is Rs. 14051.57 crore.
The promoters holding in the company stood at 73.64% while Institutions and Non-Institutions held 8.86% and 17.32% respectively.
Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 75mg tablets of Clopidogrel bisulfate and a tentative approval for the tablets containing 300mg Clopidogrel bisulfate, which are used to help reduce risk of heart attack or stroke. Clopidogrel is the generic name for the brand Plavix, marketed in the United States by Bristol-Myers Squibb. The company would be launching the product immediately.
According to IMS Health, the total market for this product in the US was over $6,500 million. Prevalence of atherosclerotic diseases is rapidly growing the world over. But by inhibiting the clotting of blood within the blood vessels, it reduces the risk of heart attacks and strokes and is one of the most used pharmaceutical products in the world.
Wockhardt will be manufacturing the Clopidogrel bisulfate API in its facility at Ankleshwar, India and the tablets of Clopidogrel at its facility in Aurangabad, India. The technology for the API and the tables were developed in-house.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s , the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1213.90 |
| Cipla | 1486.30 |
| Lupin | 2069.95 |
| Zydus Lifesciences | 948.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
